PRAX250516C100000
- 23.20
- 0.000.00%
Praxis Precision Medicines Newsroom
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $76 to $105
Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating
Truist Financial Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX)
Analysts Conflicted on These Healthcare Names: Cigna (CI), Praxis Precision Medicines (PRAX) and Mettler-Toledo (MTD)
Praxis Precision Medicine Analyst Ratings
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $105
Praxis Precision Med Price Target Maintained With a $105.00/Share by HC Wainwright & Co.
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $85
Praxis Precision Medicine Analyst Ratings
Promising Future for Praxis Precision Medicines: Buy Rating Backed by Robust Epilepsy Portfolio and Strategic Catalysts
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $65 to $120
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $65 to $105
Baird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $73
Praxis Precision Med Price Target Cut to $85.00/Share From $150.00 by Needham
Praxis Precision Med Is Maintained at Buy by Needham
Praxis Precision Medicine Analyst Ratings
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $120
Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position